Navigation Links
Data Monitoring Committee Unanimously Recommends Continuation of Celsion's Phase III ThermoDox® HEAT Study to Treat Primary Liver Cancer
Date:9/30/2010

cal resection of the tumor; however 80% to 90% of patients are ineligible for surgery.  Radio frequency ablation (RFA) has increasingly become the standard of care for non-resectable liver tumors, but the treatment becomes less effective for larger tumors. There are few non-surgical therapeutic treatment options available as radiation therapy and chemotherapy are largely ineffective in the treatment of primary liver cancer.

About ThermoDox® and the Phase III HEAT StudyThermoDox® is a proprietary heat-activated liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers.  In the HEAT study, ThermoDox is administered intravenously in combination with RFA.  A thermal zone created by the RFA releases the entrapped doxorubicin from the liposome. This delivery technology enables high concentrations of doxorubicin to be deposited preferentially at the targeted tumor.

For primary liver cancer, ThermoDox® is being evaluated in a 600 patient global Phase III study at 75 clinical sites under an FDA Special Protocol Assessment. The study is designed to evaluate the efficacy of ThermoDox in combination with RFA when compared to patients who receive RFA alone as the control. The primary endpoint for the study is progression-free survival (PFS) with a secondary confirmatory endpoint of overall survival.  A pre-planned, interim efficacy analysis will be performed by an independent Data Monitoring Committee when enrollment in the trial is complete and 50 percent of the PFS events are realized in the study population.  Additional information on the Company's ThermoDox® clinical studies may be found at http://www.clinicaltrials.gov.

About CelsionCels
'/>"/>

SOURCE Celsion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ACC Concerned Over Reporting of Biomonitoring Results
2. Xenomics Announces Issuance of a US Patent That Covers Use of Transrenal Nucleic Acid Technology for Infectious Disease Diagnostics and Monitoring
3. FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer
4. Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
5. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
6. Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home
7. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
8. Independent Studies Report on Possible Roles for Cylexs Immune Cell Function Assay in Monitoring of Heart and Lung Transplant Recipients
9. University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
10. eRT Announces the Availability of the Suicidality Monitoring System(TM) For Clinical Trials
11. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Aug. 22, 2014  Landauer, Inc. (NYSE: ... radiation measurement and monitoring, outsourced medical physics services and ... William E. Saxelby , its President and Chief Executive ... Executive Officer and as a member of the Board ... will be replaced on an interim basis by ...
(Date:8/21/2014)... AUSTIN, Texas , Aug. 21, 2014  Vermillion, ... company focused on gynecologic cancers and women,s health, has ... of Sales and Managed Markets. Ms. Bauzon ... traction and expanding payer coverage for laboratory services companies. ... most recently with PerkinElmer, Inc., where she held the ...
(Date:8/21/2014)... Aug. 21, 2014 /CNW/ - Eisai Limited is pleased to ... the first-of-its-kind comic book available in Canada ... designed specifically to educate children and their parents about epilepsy, ... affecting more than 300,000 Canadians. Eisai is guided by ... , in which the patient is central – there was ...
Breaking Medicine Technology:Landauer, Inc. Announces Executive Management Change 2Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2
... INDIANAPOLIS, Nov. 2, 2010 Eli Lilly and Company (NYSE: ... focused on diabetes in China, where the incidence of the disease ... in Shanghai in the second half of 2011, will focus on ... leadership in this disease area and the priority Lilly places on ...
... Back Awards is now accepting nominations to honor individuals ... The Welcome Back Awards , now in its 13th ... to recognize outstanding achievements in the fight against depression and ... Welcome Back Awards continue to motivate healthcare providers ...
Cached Medicine Technology:Eli Lilly and Company to Open a Diabetes-Focused Research Center in China 2Eli Lilly and Company to Open a Diabetes-Focused Research Center in China 3Eli Lilly and Company to Open a Diabetes-Focused Research Center in China 4The Welcome Back Awards Seeks Nominations to Honor Leaders in the Depression Community 2The Welcome Back Awards Seeks Nominations to Honor Leaders in the Depression Community 3
(Date:8/22/2014)... somatic mutation at amino acid 918 in the RET ... cell lung cancer (SCLC) tumors and enforced expression of ... signaling and cell growth. , SCLC is a highly ... lung cancers and is strongly associated with tobacco smoking. ... examined for genomic alterations and targeted therapies are approved ...
(Date:8/22/2014)... 22, 2014 Paying tuition and other ... the coming year for four nurse educators pursuing advanced ... League for Nursing Foundation for Nursing Education . This ... $28,000, $10,000 more than in 2013, thanks to these ... and Elizabeth Isaac Marcil Endowment Funds, both donated by ...
(Date:8/22/2014)... 22, 2014 Testosterone treatment lawsuits ... U.S. courts on behalf of men who allegedly ... of prescription low testosterone therapies, Bernstein Liebhard LLP ... was filed against Pfizer Inc. on July 31st ... heart issues due to his use of Depo-Testosterone. ...
(Date:8/22/2014)... CarePoint Health is proud to ... Geriatrics, Hospice and Palliative Care, Dr. Michelle Reisner, ... Their system welcomes Dr. Reisner to the community. ... CarePoint Health Medical Group, a comprehensive network of ... a wide range of specialties. This latest acquisition ...
(Date:8/22/2014)... -- Back-to-school time provides an opportunity for parents to ... schedules, an expert suggests. "Forget New Year,s resolutions; ... be the start of a new fitness and exercise ... at the University of the Sciences in Philadelphia, said ... activities likely to build up, "it,s important for mom ...
Breaking Medicine News(10 mins):Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:With Kids in School, Parents Can Work Out 2
... Promote Patient Safety for Care Abroad, CHICAGO, ... considering traveling abroad for medical care, new guiding,principles ... American Medical,Association,s (AMA) annual policy-making meeting. The nine ... care abroad for consideration,by patients, employers, insurers and ...
... and ,lack of time, as, the top three factors that ... ... 17 Findings from a survey,released today reveal that the vast ... less than half of those who,consider making lifestyle changes (46%) are ...
... Functioning in Fibromyalgia Patients, INDIANAPOLIS, June ... (FDA) has approved Cymbalta(R) (duloxetine HCl) for ... disorder, Eli Lilly,and Company (NYSE: LLY ... serotonin-,norepinephrine reuptake inhibitor with proven efficacy for ...
... FRANCISCO, June 16 Following a study,indicating that strong ... community, Asian & Pacific Islander Wellness Center has,developed a ... of,stigma in the Chinese community., Joan Chen generously ... for the TalkAIDS campaign, where she asks "Don,t think ...
... 16 The Concerned Shareholders of Biovail,Corporation (NYSE: BVF ... of Biovail Corporation:, , June 16, 2008, William ... Mississauga Road Mississauga, Ontario l5N 8M5, Dear Mr. ... debate between the two of,us either Wednesday or Thursday of ...
... Product Line and International ... ... the leader,in legal holds and retention management solutions, announced it secured ... Lightspeed Venture Partners, Azure Capital, Granite,Ventures, and Cipio Partners, all renewed ...
Cached Medicine News:Health News:AMA Provides First Ever Guidance on Medical Tourism 2Health News:LIVESTRONG.COM Survey Reveals 86 Percent of Americans Attempt Changes to Improve Their Health but Less Than Half are Successful 2Health News:LIVESTRONG.COM Survey Reveals 86 Percent of Americans Attempt Changes to Improve Their Health but Less Than Half are Successful 3Health News:LIVESTRONG.COM Survey Reveals 86 Percent of Americans Attempt Changes to Improve Their Health but Less Than Half are Successful 4Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 2Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 3Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 4Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 5Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 6Health News:TalkAIDS: A&PI Wellness Center Launches a New Anti-Stigma Campaign With International Star Joan Chen 2Health News:Letter Challenges Biovail CEO to a Debate 2Health News:Letter Challenges Biovail CEO to a Debate 3Health News:PSS Systems Secures $18 Million in Financing 2Health News:PSS Systems Secures $18 Million in Financing 3Health News:PSS Systems Secures $18 Million in Financing 4
... stabilized hyaluronic acid-based dermal filler and ... the U.S. market. It is indicated ... facial wrinkles and folds (such as ... under the skins surface to replenish ...
... Response is a whole blood ... be used at the point-of-care. ... screen and data management features, ... options. QC and operator lockout ...
... clinically proven aminophylline directly to the area ... reduction with the aminophylline containing cream has ... increase in the firmness of the thighs. ... skin where it causes the body fat ...
... is a unique, non-invasive way of ... of cellulite and improving overall skin ... was used to rehabilitate scars, burns ... surprising side-affect was discovered - the ...
Medicine Products: